COMFORT II Study Shows Ruxolitinib as a Very Durable Treatment for MPN

COMFORT II Study Shows Ruxolitinib as a Very Durable Treatment for MPN

ASHReport

4 years
420 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Aaron Gerds, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses how the COMFORT II Study Shows Ruxolitinib as a Very Durable Treatment for MPN from ASH 2015
Up Next Autoplay